Mirvetuximab soravtansine (MIRV) is an antibody drug conjugate comprised of a folate receptor alpha-targeted monoclonal antibody and the anti-tubulin maytansinoid payload, DM4. Here the authors report ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results